Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal

This article was originally published in The Pink Sheet Daily

04 Jan 2016
News

Executive Summary

Phase I/II trial will combine Syndax's entinostat, an HDAC inhibitor, with Pfizer/Merck KGaA's PD-L1 inhibitor avelumab. The antibody is the first immunotherapy to reach Phase III in platinum-resistant/refractory ovarian cancer.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Clinical Trials

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079069

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079069

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal

News

Executive Summary

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert